Evidence map›Paper›PMID 27125308›Full record

ArticleLeukemia2016

Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.

P Sontakke, M Carretta, J Jaques, A Z Brouwers-Vos, L Lubbers-Aalders, H Yuan, J D de Bruijn, A C M Martens, E Vellenga, R W J Groen and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. OncogeneScience advances · 2024
    Article
  3. Article
  4. Review
  5. Culturing patient-derived malignant hematopoietic stem cells in engineered and fully humanized 3D niches.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. FLT3Leukemia · 2019
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

P SontakkeDepartment of Experimental Hematology, Cancer Research Center Groningen (CRCG), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
M CarrettaDepartment of Experimental Hematology, Cancer Research Center Groningen (CRCG), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J JaquesDepartment of Experimental Hematology, Cancer Research Center Groningen (CRCG), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
A Z Brouwers-VosDepartment of Experimental Hematology, Cancer Research Center Groningen (CRCG), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
L Lubbers-AaldersDepartment of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
H YuanXpand Biotechnology BV, Bilthoven, The Netherlands.
J D de BruijnQueen Mary University of London, School of Engineering and Materials Science (SEMS), London, UK.
A C M MartensDepartment of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
E VellengaDepartment of Experimental Hematology, Cancer Research Center Groningen (CRCG), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
R W J GroenDepartment of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
J J SchuringaDepartment of Experimental Hematology, Cancer Research Center Groningen (CRCG), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
University Medical Center Groningen · NLAmsterdam UMC Location VUmc · NLQueen Mary University of London · GBUniversity of Groningen · NLXpand Biotechnology (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although NOD-SCID IL2Rγ

Indexed as

Disease Models, AnimalFusion Proteins, bcr-ablMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionAnimalsBone MarrowHumansLeukemia, Myeloid, AcuteMicePrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation, HeterologousFusion Proteins, bcr-ablMLL-AF9 fusion protein, humanMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, Fusion

Identifiers

PMID27125308
OpenAlexW2343786116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.